Re: Farmas USA
OCAT
Van saliendo documentos
De las FAQ
We expect the transaction will close by the end of this year or in January 2016. As with any similarly structured public company acquisition, the Merger can close only if Ocata’s shareholders tender a sufficient number of shares in the tender offer to be commenced by Astellas and certain other conditions are met. In the meantime, Ocata and Astellas will continue to do business as separate entities
Email del jefe a los empleados de hoy:
Dear colleagues,
Today marks a historic milestone for Ocata. This morning, we announced that Ocata has entered into a definitive agreement to be acquired by Astellas Pharma Inc., a leading Tokyo-based pharmaceutical company that is seeking to build therapeutic area capabilities in ophthalmology and regenerative medicine.
We will have a town hall on Tuesday morning 11/10/2015 at 9am to address your questions. In the meantime, the most important thing for you to remember is that we will continue to run Ocata as we have always run Ocata — practicing the best science that will improve the lives of future generations.
Our board believes that now is the right time to join forces with Astellas, because we have the opportunity to accelerate the development and commercialization of our pipeline that we have worked so hard to build. Not only will Astellas’ strong financial position help maximize the value of Ocata’s R&D programs, but also, it will help secure continued funding for our ongoing R&D. For several years now, Ocata has been at the forefront of delivering innovation to the biotech industry. With the backing of Astellas and collaboration with new global partners, we will be able to do even more. With today’s news, we catapult from a small biotech company to being part of a world leader in innovative healthcare.
Astellas shares Ocata’s history of innovation. If you know someone who has had a transplant, they may take tacrolimus to avoid organ rejection. An Astellas scientist discovered tacrolimus in a soil sample taken from the foot of Mount Tsukuba in Japan. Tacrolimus is one of the many innovative products in Astellas’ portfolio. It’s exciting to work with a company that has a legacy of changing the world through innovation.
Together, our opportunity is enormous. Ultimately, it is patients who will benefit from our collaboration. While change is never easy, I believe our best days are ahead of us. I have also attached a copy of a letter from Astellas’ CEO, Yoshihiko Hatanaka expressing his delight at our future together.
Yours sincerely
Paul K. Wotton Ph.D.
President and CEO
«Después de nada, o después de todo/ supe que todo no era más que nada.»
_foro.png?1447195398)